RCUS Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -191.67% compared to Arcus Biosciences's net margin of 8.48%. Arcus Biosciences's return on equity of -46.73% beat Eli Lilly and's return on equity of 66.4%.

Arcus Biosciences has a consensus price target of $33.13, signalling upside risk potential of 109.73%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.91%. Given that Arcus Biosciences has higher upside potential than Eli Lilly and, analysts believe Arcus Biosciences is more attractive than Eli Lilly and.

Arcus Biosciences has a beta of 0.877, which suggesting that the stock is 12.314% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Arcus Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. Arcus Biosciences pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcus Biosciences quarterly revenues are $48M, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Arcus Biosciences's net income of -$92M is lower than Eli Lilly and's net income of $970.3M. Notably, Arcus Biosciences's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 85.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences is 5.17x versus 17.57x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -191.67% compared to Arcus Biosciences's net margin of -49.65%. Arcus Biosciences's return on equity of -46.73% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Arcus Biosciences has a consensus price target of $33.13, signalling upside risk potential of 109.73%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 557.2%. Given that NovaBay Pharmaceuticals has higher upside potential than Arcus Biosciences, analysts believe NovaBay Pharmaceuticals is more attractive than Arcus Biosciences.

Arcus Biosciences has a beta of 0.877, which suggesting that the stock is 12.314% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Arcus Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcus Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Arcus Biosciences quarterly revenues are $48M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Arcus Biosciences's net income of -$92M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Arcus Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences is 5.17x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -191.67% compared to Arcus Biosciences's net margin of -2357.27%. Arcus Biosciences's return on equity of -46.73% beat Palatin Technologies's return on equity of --.

Arcus Biosciences has a consensus price target of $33.13, signalling upside risk potential of 109.73%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Arcus Biosciences, analysts believe Palatin Technologies is more attractive than Arcus Biosciences.

Arcus Biosciences has a beta of 0.877, which suggesting that the stock is 12.314% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Arcus Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcus Biosciences pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Arcus Biosciences quarterly revenues are $48M, which are larger than Palatin Technologies quarterly revenues of $350K. Arcus Biosciences's net income of -$92M is lower than Palatin Technologies's net income of -$7.8M. Notably, Arcus Biosciences's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences is 5.17x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -191.67% compared to Arcus Biosciences's net margin of 36.03%. Arcus Biosciences's return on equity of -46.73% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Arcus Biosciences has a consensus price target of $33.13, signalling upside risk potential of 109.73%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 46.94%. Given that Arcus Biosciences has higher upside potential than Regeneron Pharmaceuticals, analysts believe Arcus Biosciences is more attractive than Regeneron Pharmaceuticals.

Arcus Biosciences has a beta of 0.877, which suggesting that the stock is 12.314% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Arcus Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcus Biosciences pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Arcus Biosciences quarterly revenues are $48M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Arcus Biosciences's net income of -$92M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Arcus Biosciences's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences is 5.17x versus 5.96x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.